BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.
Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
Becton Dickinson to break off biosciences, diagnostic solutions
Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.
BD Intends to Separate Biosciences and Diagnostic Solutions Business
The board of directors of Franklin Lakes-based, global medical technology company BD, has unanimously authorized BD management
Becton Dickinson to Split from Bioscience and Diagnostic Solutions Arms
American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic solutions arms to become
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-oriented investments and capital allocation.
Becton looks to separate biosciences and diagnostic solutions after upbeat quarterly results
(This Feb. 5 story has been refiled to correct the name of the unit to biosciences and diagnostic solutions, from life sciences, in the headline and paragraphs 1 and 4) (Reuters) - Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday,
BD to separate Biosciences and Diagnostic Solutions business
The plan is to position the New BD as a differentiated MedTech leader and enable optimized investment to accelerate the innovation pipeline and ongoing margin enhancement through BD Excellence to further fund growth.
FierceBiotech6h
BD bids farewell to its diagnostic, bioscience divisions with company split
After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...
MassDevice11h
BD announces intent to sell Life Sciences business, beats Street in Q1
BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.
Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript
At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...
Becton Dickinson to separate biosciences, diagnostic solutions business
BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...